New York, NY – October 10, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), in the Company’s up-listing to the NASDAQ Capital Market. The Sichenzia Ross Ference LLP team was led by Gregory Sichenzia and partner Barrett DiPaolo. The up-listing is effective for trading on October 10, 2019, and RLMD’s common stock will trade under its existing stock symbol, “RLMD.”
“We applaud Relmada on the achievement of this important milestone, one that positions the Company to capitalize on its market objectives while it continues to develop its therapies for treatment of central nervous system disorders,” said Gregory Sichenzia, founding partner of Sichenzia Ross Ference LLP.
